Loading
A Swedish study checking Elypta's sugar-molecule blood and urine test for many cancers on stored samples from people without symptoms.
LEVANTIS-0087A (NCT05235009) is an observational study sponsored by Elypta. It is a retrospective case-control validation of free GAGome-based multi-cancer early detection tests in adults without symptoms and without recent cancer.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 9,170 participants, a start on 1 February 2022 and primary completion expected in December 2025.
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/